Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer-Reference-Cited by-同舟云学术

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer

Published:2001-06 Issue:9 Volume:37 Page:1132-1140
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Namer M,Soler-Michel P,Turpin F,Chinet-Charrot P,de Gislain C,Pouillart P,Delozier T,Luporsi E,Etienne P.L,Schraub S,Eymard J.C,Serin D,Ganem G,Calais G,Maillart P,Colin P,Trillet-Lenoir V,Prevost G,Tigaud D,Clavère P,Marti P,Romieu G,Wendling J.L

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference37 articles.

1. Randomised phase II study of epirubicin–vindesine versus mitoxantrone–vindesine in metastatic breast cancer;Hausmaninger;Eur. J. Cancer,1995

2. ABC of breast diseases;Leonard;BMJ,1994

3. New treatments for breast cancer;Smith;Semin. Oncol.,1996

4. Epirubicin /vinorelbine as first line therapy in metastatic breast cancer;Baldini;Breast Cancer Res. Treat.,1998

5. Chemotherapy and survival in advanced breast cancer;A'Hern;Br. J. Cancer,1993

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials;Clinical Breast Cancer;2018-02

2. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis;Breast Cancer Research and Treatment;2015-11-23

3. A Systematic Review of Vinorelbine for the Treatment of Breast Cancer;The Breast Journal;2013-01-16

4. Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development;Current Breast Cancer Reports;2013-01-03

5. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study;Journal of Experimental & Clinical Cancer Research;2011-04-12